Kailera Therapeutics (NASDAQ:KLRA) Stock Jumps 8.3% – What’s Next?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) traded up 8.3% during mid-day trading on Tuesday. The stock traded as high as $12.51 and last traded at $12.38. 239,776 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 869,952 shares. The stock had previously closed at $11.43.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Trading Up 0.2%

The business has a 50 day simple moving average of $13.94.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, equities research analysts predict that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

Large investors have recently made changes to their positions in the stock. Tidal Investments LLC bought a new position in shares of Kailera Therapeutics during the 2nd quarter worth approximately $309,000. Mirador Capital Partners LP acquired a new position in shares of Kailera Therapeutics during the 3rd quarter worth approximately $666,000. Squarepoint Ops LLC bought a new stake in Kailera Therapeutics in the 2nd quarter valued at $993,000. State Street Corp bought a new stake in Kailera Therapeutics in the 2nd quarter valued at $19,126,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in Kailera Therapeutics in the 2nd quarter valued at $24,233,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.